Pfizer believes that its highest payoff for R&D will be in oncology, pain, inflammation, diabetes, Alzheimer’s’ disease and schizophrenia. Consequently, it will minimize its work on heart disease, anemia, osteoporosis, liver disease, obesity, PAD, and arthritis. This shift also reflects Pfizer’s greater interest in biologics over small molecules. MORE